GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (ASX:ACR) » Definitions » Cash, Cash Equivalents, Marketable Securities
中文

Acrux (ASX:ACR) Cash, Cash Equivalents, Marketable Securities : A$4.57 Mil (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Acrux Cash, Cash Equivalents, Marketable Securities?

Acrux's quarterly cash, cash equivalents, marketable securities increased from Dec. 2022 (A$4.35 Mil) to Jun. 2023 (A$6.23 Mil) but then stayed the same from Jun. 2023 (A$6.23 Mil) to Dec. 2023 (A$4.57 Mil).

Acrux's annual cash, cash equivalents, marketable securities declined from Jun. 2021 (A$15.27 Mil) to Jun. 2022 (A$5.83 Mil) but then increased from Jun. 2022 (A$5.83 Mil) to Jun. 2023 (A$6.23 Mil).


Acrux Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Acrux's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acrux Cash, Cash Equivalents, Marketable Securities Chart

Acrux Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.15 9.21 15.27 5.83 6.23

Acrux Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.60 5.83 4.35 6.23 4.57

Acrux Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Acrux  (ASX:ACR) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Acrux Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Acrux's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Acrux (ASX:ACR) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (ASX:ACR) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
Address
103-113 Stanley Street, West Melbourne, Melbourne, VIC, AUS, 3003
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.